Clinical practice
PAN Xiaoping, ZHENG Juan, GAO Bing, YANG Yanhui.
Objective: To explore the effect of the combined application of terbutaline nebulized inhalation and azithromycin sequential therapy on patients with mycoplasma pneumonia (MPP). Method: A total of 82 patients with MPP admitted to Huanggang Maternal and Child Health Hospital from June 2021 to June 2024 were selected. According to the random number table method, the patients were divided into the control group (n=41, treated with sequential azithromycin therapy) and the observation group (n=41, treated with terbutaline nebulized inhalation on the basis of the treatment in the control group). The treatment course of both groups was 14 days. The clinical efficacy, symptom relief time, serum inflammatory factors, lung function and adverse reactions of the two groups were compared. Result: The total effective rate of treatment in the observation group (95.12%) was higher than that in the control group (78.05%). The relief time of fever symptoms in the observation group was (2.69±0.42) days, that of cough symptoms was (5.11±1.01) days, that of pulmonary rales symptoms was (5.08±1.02) days, and that of wheezing symptoms was (2.01±0.11) days, which were shorter than those in the control group. After treatment in the observation group, interleukin-6 (IL-6) was (15.54±2.11) pg/mL, C-reactive protein (CRP) was (6.04±1.08) mg/L, tumor necrosis factor -α (TNF-α) was (8.11±1.21) ng/L, and interferon -γ (INF-γ) was (14.04±2.05) ng/mL, which were lower than those of the control group. After treatment, the maximum expiratory flow rate (PEF) (3.39±0.49) L/min, forced vital capacity (FVC) (3.72±0.31) L, midcourse expiratory flow rate (MMEF) (1.85±0.25) L/S, and forced expiratory volume in one second (FEV1) (1.40±0.25) L in the observation group were higher than those in the control group. The difference was statistically significant (P<0.05). There was no statistically significant difference in adverse reactions between the two groups (P>0.05). Conclusion: In patients with MPP, the sequential therapy of terbutaline nebulized inhalation combined with azithromycin has a significant effect in terms of disappearance of clinical symptoms, reduction of inflammatory response, improvement of lung function, etc., and has a relatively high safety.